| Literature DB >> 23227083 |
Selena Viganò1, Daniel T Utzschneider, Matthieu Perreau, Giuseppe Pantaleo, Dietmar Zehn, Alexandre Harari.
Abstract
The functional avidity is determined by exposing T-cell populations in vitro to different amounts of cognate antigen. T-cells with high functional avidity respond to low antigen doses. This in vitro measure is thought to correlate well with the in vivo effector capacity of T-cells. We here present the multifaceted factors determining and influencing the functional avidity of T-cells. We outline how changes in the functional avidity can occur over the course of an infection. This process, known as avidity maturation, can occur despite the fact that T-cells express a fixed TCR. Furthermore, examples are provided illustrating the importance of generating T-cell populations that exhibit a high functional avidity when responding to an infection or tumors. Furthermore, we discuss whether criteria based on which we evaluate an effective T-cell response to acute infections can also be applied to chronic infections such as HIV. Finally, we also focus on observations that high-avidity T-cells show higher signs of exhaustion and facilitate the emergence of virus escape variants. The review summarizes our current understanding of how this may occur as well as how T-cells of different functional avidity contribute to antiviral and anti-tumor immunity. Enhancing our knowledge in this field is relevant for tumor immunotherapy and vaccines design.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23227083 PMCID: PMC3511839 DOI: 10.1155/2012/153863
Source DB: PubMed Journal: Clin Dev Immunol ISSN: 1740-2522
Figure 1Schematic representation, definition, technique of measurement and readout of TCR affinity and functional avidity.
Figure 2Proposed Model of the relationships between antigen exposure and functional avidity of T cells. Functional avidity of virus-specific CD8 T cells during (a) acute infection and then translation after transition to the chronic phase for (b) uncontrolled virus infection (such as progressive HIV infection) or (c) controlled but persistent virus infection (such as nonprogressive HIV, cytomegalovirus [CMV], or Epstein-Barr virus [EBV], or (d) after virus clearance (such as influenza [Flu] or adenovirus [Ad5], or early treatment of acute HIV infection). (e) Increase in the functional avidity of HIV-specific CD8 T cells of patients treated during acute infection who interrupted the antiretroviral therapy [TI] and experienced a virus rebound.